Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1405-1412

  Sandler, Alan B ^a   Schiller, Joan H ^a   Gray, Robert ^a   Dimery, Isaiah ^a   Brahmer, Julie ^a   Samant, Meghna ^a   Wang, Lisa I ^a   Johnson, David H ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INOPERABLE CANCER; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; THORAX RADIOGRAPHY; BLEEDING; CASE CONTROL STUDY; LUNG DISEASE; LUNG TUMOR; PATHOLOGY; RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; COHORT STUDIES; HEMORRHAGE; LUNG DISEASES; LUNG NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 63049122188     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.2412     Document Type: Article

References (19)

1. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22:2184-2191, 2004
2. Novotny WF, Holmgren E, Griffing S, et al: Identification of squamous cell histology and central, cavitary tumors as possible risk factors for pulmonary hemorrhage (PH) in patients with advanced NSCLC receiving bevacizumab (BV). Proc Am Soc Clin Oncol 20:330a, 2001 (abstr 1318)
3. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006
4. Socinski MA, Novello S, Sanchez JM, et al: Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. J Clin Oncol 24:49s, 2006 (suppl; abstr 7001)
5. Adjei AA, Molina JR, Hillman SL, et al: A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 25:396s, 2007 (suppl; abstr 7547)
6. Gauler TC, Besse B, Meric JB, et al: Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily or twice daily at 1,250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 25:394s, 2007 (suppl; abstr 7541)
7. Miller RR, McGregor DH: Hemorrhage from carcinoma of the lung. Cancer 46:200-205, 1980
8. Salajka F: Occurrence of haemoptysis in patients with newly diagnosed lung malignancy. Schweiz Med Wochenschr 129:1487-1491, 1999
9. Pentheroudakis G, Kostadima L, Fountzilas G, et al: Cavitating squamous cell lung carcinomadistinct entity or not? Analysis of radiologic, histologic, and clinical features. Lung Cancer 45:349-355, 2004
10. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
11. Rothman KJ, Greenland S: Modern epidemiology (ed 2). Philadelphia, PA, Lippincott Williams and Wilkins, 1998
12. Agresti A: Categorical Data Analysis. New York, NY, John Wiley & Sons, 1990
13. Robins J, Breslow N, Greenland S: Estimators of the Mantel-Haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 42:311-323, 1986
14. Seo JB, Im JG, Goo JM, et al: Atypical pulmonary metastases: Spectrum of radiologic findings. Radiographics 21:403-417, 2001
15. Mouroux J, Padovani B, Elkaim D, et al: Should cavitated bronchopulmonary cancers be considered a separate entity? Ann Thorac Surg 61:530-532, 1996
16. Chaudhuri MR: Primary pulmonary cavitating carcinomas. Thorax 28:354-366, 1973
17. Kolodziejski LS, Dyczek S, Duda K, et al: Cavitated tumor as a clinical subentity in squamous cell lung cancer patients. Neoplasma 50:66-73, 2003
18. Socinski MA, Novello S, Brahmer JR, et al: Phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26:650-656, 2008
19. Gatzemeier U, Blumenschein G, Fosella F, et al: A phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. J Clin Oncol 24:364s, 2006 (suppl; abstr 7002)